跳到正文
原文
Medical Xpress·· 2 天前AI 评分48

AI可能帮助从血液中识别早期肺癌的迹象

AI may help spot early signs of lung cancer in the blood

AI 导读

英国癌症研究中心国家生物标志物中心主任Caroline Dive教授团队正利用AI技术开发基于血液的早期肺癌检测手段,旨在提高NHS肺部筛查的准确性并拓展至目前不符合条件的非吸烟人群。

正文
Can AI help spot early signs of lung cancer in the blood?
Lung cancer cells. Credit: Anne Weston, Francis Crick Institute

In a blue-and-white van outside Asda last June, 68-year-old Eddie, a retired fishmonger from Fallowfield, near Manchester, received life-changing news.

The van belonged to the NHS—and it contained a portable scanner. Eddie and his wife Jeanette had arrived for a lung screening appointment, after being invited by their primary care doctor.

"I very nearly didn't go," recalls Eddie, who felt fit and well. But Jeanette insisted: it was no more difficult than a quick trip to the store.

"Because I smoked as a teenager and had some family history of cancer, they said that I should have a scan there and then," he remembers.

To the couple's shock, it found a dark shadow on Eddie's right lung. A week later, in the hospital, he had further tests, including a biopsy—and the couple's worst fears were confirmed: it was lung cancer. "I can't even properly remember the conversation. I was in total shock," Eddie says.

But screening has its downsides. False positives can cause stress and anxiety, while regular monitoring after surgery can be a stressful and time-consuming process. There are also potential harms from the radiation used in CT scans, even though the dose is low.

For these reasons, the NHS program currently only invites current and former smokers, whose higher cancer risk means the benefits outweigh these harms. But estimates suggest as many as 6,000 "never-smokers"—currently ineligible for screening—die from lung cancer every year.

So researchers are looking for ways to make screening more accurate, tell fast-growing tumors apart from slower-growing ones (to spare some people intensive monitoring while offering more intensive therapies to others) and extend its benefits to more people.

At the Cancer Research UK National Biomarker Centre, just minutes from the supermarket where Eddie's story began, center director professor Caroline Dive CBE and her teams are exploring an approach that could transform lung screening.

Using cutting-edge artificial intelligence (AI), they're looking for answers in people's blood…

Fishing for clues

"Scans are good at finding people with stage 1 disease, almost all of whom will have surgery and a good chance of cure," says Dive, who has dedicated much of her career to early cancer detection. "But about one in five will go on and relapse. And that means, in some folks, that an early tumor has already sent out the seeds of metastasis" and begun to spread.

Dive is a world-renowned expert in blood-based cancer biomarkers: subtle changes in the levels or structure of molecules in the blood that reveal the disease's presence. And at Cancer Research UK, we're now supporting her team to tackle two key questions in lung screening.

"First, can we use blood tests to find early lung cancers?" says Dive. Early tumors release molecules and cells into the bloodstream—could these form the basis for a blood test, or "liquid biopsy," to augment CT scans and boost their accuracy?

"Since 2016, we've been working closely with one of the pioneers of community-based lung screening in Manchester: professor Phil Crosbie and his team at Wythenshawe Hospital," says Dive. Together, they hope that, by using sophisticated techniques to compare samples from people with and without early lung cancer, they can identify molecular signatures that could lead to a sensitive and informative blood test.

But with the multitude of different molecules and cells circulating in the blood, knowing which ones signal an early lung cancer is a formidable challenge. To help spot patterns hiding in this complexity, Caroline's team is turning to one of the most promising developments in modern research: AI.

Nature's most complex mixture

Blood is one of nature's most complex liquids. Billions of cells—chiefly oxygen-carrying red blood cells and various flavors of immune cells—float in a watery soup containing countless biomolecules. These include tens of thousands of different types of proteins; sugars, fats and other metabolites; and fragments of genetic material (DNA and RNA) shed by dying cells—including cancer cells. And thanks to modern technologies, scientists can now measure the levels and nature of these components with astonishing accuracy.

Because these molecules reflect so many of the body's processes, a well-designed blood test can offer a window into its inner workings, including when we're ill. But developing a reliable test is challenging. Levels of different molecules naturally fluctuate: with age, infections, allergies, illness, exercise, and even with what we've eaten.

The trick, therefore, is separating the signal from the noise.

To do this, Dive's team has selected 200 pairs of blood samples from their larger collection of screening samples.

"For every sample where screening found an early lung cancer, we've been able to match a 'partner' sample from someone who remained cancer-free, but who was otherwise similar in age, sex and smoking history," she explains. This should make the cancer-related differences between samples much easier to distinguish. "We're fishing in a pond, rather than an entire ocean," she says.

And rather than relying on one type of measurement—which, Dive says, is "unlikely to get the job done"—they're taking a "multi-modal" approach, looking for patterns across a whole range of biological information sources.

For instance, using a technique called proteomics, they're precisely measuring levels of thousands of circulating proteins. For circulating DNA fragments shed by tumors, they're looking at three different features: cancer-linked mutations; chemical modifications to the DNA (including so-called methylation); and differences in the fragments' size (known as "fragmentomics"). They're looking for rare abnormal circulating cells—including cancer cells—that might offer clues. And with collaborators in the U.S., they're analyzing circulating RNA (a shorter-lived cousin of DNA).

Sifting through the data with AI

This will create an enormous data set, containing hundreds of thousands of measurements from each sample. Finding meaningful, cancer-linked patterns within it is an extraordinary challenge—and that's where AI comes in. "It's such a big puzzle, and AI will hugely speed up the process," says Dive.

The team will first train AI models using data from the first 100 pairs of cancer-positive and matched-negative samples. Then they'll test whether the best-performing AI model can identify cancer in the second 100 pairs, without the AI "knowing' which samples came from people with cancer. A key challenge will be identifying the minimum number of measurements needed to maintain accuracy across such large data sets.

Then, if successful, the next step will be a much larger study. "If—and it's a big 'if'—the data are convincing, then we'll need to work with commercial partners and organizations like Cancer Research Horizons," says Dive. "Developing a biomarker test for routine use is really challenging—and expensive."

None of this would be possible without the research networks and infrastructure that have developed in Manchester since Dive moved there in 2003, she says. "I'm hugely grateful that Cancer Research UK has given me a stable base to develop strong networks, not only in Manchester with the Christie Hospital and wider NHS trusts, but around the UK and abroad," she says. "We've got the right ingredients in the pot—now we're just going to have to see what these precious samples can tell us."

Meanwhile, Eddie's most recent scan was clear, and he's looking to the future. "I had a lot to lose—I am so glad that my cancer was caught early. Not everyone is that lucky, so research to help others be diagnosed as early, like I was, is so important," he says. "We must support this crucial work for future generations, so more people can survive their cancer."

Key medical concepts

Liquid BiopsyCT Scans

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: AI may help spot early signs of lung cancer in the blood (2026, November 17) retrieved 17 November 2026 from https://medicalxpress.com/news/2026-11-ai-early-lung-cancer-blood.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com